Acenocoumarol

PreclinicalSmall molecule

Roche

Acenocoumarol is one of 51 small molecule programs targeting Stroke. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

AnticoagulationCompleted

StrokePreclinical

Active, not recruiting

AnticoagulationPreclinical

Completed

Competition

Competitive Landscape

150 competitors in Stroke

#DrugCompanyPhaseTrials

Keppra

UCB

Phase 3

2 2

Zometa

Pfizer

Preclinical

1 3

Savella

AbbVie

Preclinical

1 4

Repatha

Proamatine

Zantac 150

1 7

Alka-Seltzer

AAbbott

Preclinical

1 8

Haldol

DDePuy Orthopaedics

Preclinical

1 9

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 10

Inderal

Mylan Pharmaceuticals Inc

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rivaroxaban1 trial

Rivaroxaban Plus Aspirin to Manage Recurrent Venous Thromboembolic Events

Completed·IInstituto Mexicano del Seguro Social·Phase 2/3·NCT05515120·58 enrolled

Venous thrombosis1 trial

Long-Term Low-Molecular-Weight Heparin Versus Oral Anticoagulants in Deep Venous Thrombosis

Completed·HHospital Universitari de Bellvitge·Phase 4·NCT00689520·241 enrolled

Anticoagulant1 trial

Start or STop Anticoagulants Randomised Trial (SoSTART)

Completed·UUniversity of Edinburgh·Phase 3·NCT03153150·203 enrolled

Anticoagulation1 trial

Safety Study of Vitamin K2 During Anticoagulation in Human Volunteers

Completed·MMaastricht University·N/A·NCT00512928·20 enrolled

Metastatic1 trial

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Completed· Roche logo

Roche·Phase 1·NCT01851824·9 enrolled

3 more indications

Pulmonary Embolism1 trial

Tinzaparin in the Treatment of the Acute Pulmonary Embolism

Completed·—·Phase 4·NCT00711308·102 enrolled

Stroke1 trial

Dabigatran Study in the Early Phase of Stroke. New Neuroimaging Markers and Biomarkers Study (SEDMAN STUDY)

Unknown status·HHospital Mutua de Terrassa··NCT02742480·500 enrolled

Thrombosis1 trial

Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography (RETORIC)

Unknown status·SSemmelweis University Heart and Vascular Center·Phase 4·NCT02826200·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Acenocoumarol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Acenocoumarol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Acenocoumarol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Roche

Acenocoumarol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rivaroxaban1 trial

Venous thrombosis1 trial

Anticoagulant1 trial

Anticoagulation1 trial

Metastatic1 trial

Pulmonary Embolism1 trial

Stroke1 trial

Thrombosis1 trial

References

Drug Info

Quick Facts

Related News